Peer Reviewed
Drug update
Using a combination of fluticasone/salmeterol in the treatment of COPD
Abstract
Fluticasone/salmeterol combination therapy (Seretide) should be considered in patients with moderate or severe COPD that is not adequately controlled by other therapy.
Key Points
What is fluticasone/salmeterol combination therapy?
Fluticasone/salmeterol (Seretide) is a combination of a long-acting beta2 agonist salmeterol and an inhaled corticosteroid fluticasone. It is available in a dry powder form (Seretide Accuhaler) or in a CFC-free inhaler (Seretide MDI). The indication to prescribe fluticasone/salmeterol has recently been extended from asthma to include chronic obstructive pulmonary disease (COPD).
Purchase the PDF version of this article
Already a subscriber? Login here.